Candel Therapeutics Stock Investor Sentiment
| CADL Stock | USD 5.04 0.90 21.74% |
About 67 percent of all Candel Therapeutics' institutional investors are curious in acquiring. The analysis of the overall investor sentiment regarding Candel Therapeutics suggests that many traders are confidant. Candel Therapeutics' investing sentiment shows overall attitude of investors towards Candel Therapeutics.
Candel |
Candel Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Candel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Candel Therapeutics that are available to investors today. That information is available publicly through Candel media outlets and privately through word of mouth or via Candel internal channels. However, regardless of the origin, that massive amount of Candel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Candel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Candel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Candel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Candel Therapeutics alpha.
Candel Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Benz Edward J. Jr of 14240 shares of Candel Therapeutics at 1.22 subject to Rule 16b-3 | 08/29/2024 |
2 | Acquisition by Manning Paul B of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3 | 09/20/2024 |
3 | Acquisition by Aguilar-cordova Estuardo of 6214 shares of Candel Therapeutics at 7.0091 subject to Rule 16b-3 | 10/01/2024 |
4 | Disposition of 26988 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.92 subject to Rule 16b-3 | 10/02/2024 |
5 | Disposition of 1800 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.85 subject to Rule 16b-3 | 10/03/2024 |
6 | Disposition of 15000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.05 subject to Rule 16b-3 | 10/11/2024 |
7 | Disposition of 15000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.02 subject to Rule 16b-3 | 10/14/2024 |
8 | Candel therapeutics investor sells 243,834 in stock | 10/15/2024 |
9 | Acquisition by Tak Paul Peter of 180108 shares of Candel Therapeutics subject to Rule 16b-3 | 10/18/2024 |
10 | Disposition of 12645 shares by Barone Francesca of Candel Therapeutics at 5.9734 subject to Rule 16b-3 | 10/22/2024 |
11 | Disposition of 1194 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.72 subject to Rule 16b-3 | 10/24/2024 |
12 | Disposition of 1597 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.8 subject to Rule 16b-3 | 10/25/2024 |
13 | Disposition of 6000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.38 subject to Rule 16b-3 | 10/30/2024 |
14 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.3 subject to Rule 16b-3 | 10/31/2024 |
15 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.27 subject to Rule 16b-3 | 11/01/2024 |
16 | Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond... | 11/05/2024 |
17 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.33 subject to Rule 16b-3 | 11/06/2024 |
18 | Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 | 11/07/2024 |
19 | Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.92 subject to Rule 16b-3 | 11/08/2024 |
20 | Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 11/14/2024 |
21 | Acquisition by Tak Paul Peter of 12900 shares of Candel Therapeutics at 1.55 subject to Rule 16b-3 | 11/21/2024 |
Check out Candel Therapeutics Hype Analysis, Candel Therapeutics Correlation and Candel Therapeutics Performance. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.